Diamyd Medical - Developing precision therapies for type 1 diabetes

I am very happy to announce that all eight European countries where DIAGNODE-3 is ongoing have randomized patients to the trial and we hope to start the trial in the US shortly.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 3 22/23

A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine Diamyd^®, an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on a baculovirus-insect cell expression system.

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read more

Diabetes

10-20% of the more than 463 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® and the regenerative and immunomodulatory therapy Remygen^® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in Type 1 Diabetes is being confirmed in the precision medicine Phase III trial DIAGNODE-3. A booster regimen with Diamyd^® is being evaluated in the Phase II trial DIAGNODE-B.

Order GAD for preclinical research

ORDER

Share This Page

GAD PRODUCTS

Order GAD for preclinical research

the Phase 3 trial DIAGNODE-3

and other ongoing trials

Developing precision therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd^®

Notification of attendance at Extra General Meeting

Press Releases

Events & Mediawatch

Financial Reports

Company Presentation

Calendar

Manufacturing of GAD65 in Umeå

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Diabetes

Products

Clinical Trials

Order GAD for preclinical research

ORDER

Annual Report

Contact Us

Subscribe

Follow Us

the Phase 3 trial DIAGNODE-3

and other ongoing trials

Developing precision therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd®

Notification of attendance at Extra General Meeting

Company Presentation

Calendar

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetesThe share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Order GAD for preclinical research

Annual Report

Follow Us

with Diamyd^®

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)